Aadi Bioscience, Inc.: Clinical Trials

18 trials sponsored by Aadi Bioscience, Inc., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 3 terminated, 2 withdrawn, 1 active not recruiting. 12 Phase 2, 9 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 212Completed 7, Terminated 2, Active not recruiting 1, Recruiting 1, Withdrawn 1
Phase 19Completed 6, Terminated 2, Withdrawn 1

Follow Aadi Bioscience, Inc.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)
nab-Sirolimus, Fulvestrant - Low Grade Ovarian Serous Adenocarcinoma
Phase 2Active not recruitingUniversity of Oklahoma372024-12-262026-06-12
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
nab-sirolimus - Endometrial Cancer, Endometrioid Tumor
Phase 2RecruitingAadi Bioscience, Inc.292023-12-282025-11-13
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
nab-sirolimus - Neuroendocrine Tumors, NET
Phase 2CompletedAadi Bioscience, Inc.122023-10-202026-08-25
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
Adagrasib, nab-Sirolimus - Solid Tumor, Adult, NSCLC
Phase 1TerminatedMirati Therapeutics Inc.62023-08-072025-04-25
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
nab-sirolimus - Tumor, Solid, Tumor
Phase 1CompletedAadi Bioscience, Inc.152022-11-232026-10-28
ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome
ABI-009 - Leigh Syndrome
Phase 2WithdrawnAadi Bioscience, Inc.2022-04-302022-02-01
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
nab-sirolimus - Tumor, Tumor, Solid
Phase 2CompletedAadi Bioscience, Inc.1282022-03-102026-10-28
Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma
ABI-009, Pomalidomide, Dexamethasone - Multiple Myeloma
Phase 1WithdrawnMassachusetts General Hospital2019-05-302019-08-14
Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas
Sirolimus Albumin-bound Nanoparticles, Pazopanib hydrochloride - Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma
Phase 1 / Phase 2TerminatedUniversity of Washington192019-04-012025-04-30
A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System
ABI-009 - Neuroendocrine Tumors
Phase 2TerminatedRobert Ramirez52018-11-052021-06-10
Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
nab-sirolimus, nab-sirolimus + temozolomide, nab-sirolimus + bevacizumab - High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Phase 2CompletedAadi Bioscience, Inc.622018-08-012023-11-07
ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)
ABI-009 - Epilepsy Intractable
Phase 1CompletedSeattle Children's Hospital142018-07-312023-05-06
Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer
nab-sirolimus - Colorectal Cancer Metastatic
Phase 1 / Phase 2CompletedAadi Bioscience, Inc.602018-07-012024-01-02
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
Nab-Rapamycin, Nivolumab - Ewing Sarcoma, PEComa
Phase 1 / Phase 2CompletedSarcoma Oncology Research Center, LLC342017-08-242025-02-17
Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension
nab-sirolimus - Pulmonary Hypertension
Phase 1CompletedAadi Bioscience, Inc.152017-04-012024-11-25
A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa
nab-Sirolimus - Malignant PEComa
Phase 2CompletedAadi Bioscience, Inc.342015-10-012023-04-07
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
ABI-009, Gemcitabine - Non-muscle Invasive Bladder Cancer (NMIBC)
Phase 1 / Phase 2CompletedAadi Bioscience, Inc.212014-04-092021-06-08
Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation
ABI-009 - PEComa, Malignant, TSC1
Approved for marketingAadi Bioscience, Inc.2022-03-16

Conditions studied

Neoplasms (4)  ·  Perivascular Epithelioid Cell Neoplasms (3)  ·  Neoplasm Metastasis (2)  ·  Neuroendocrine Tumors (2)  ·  Sarcoma (2)  ·  Adenoma, Islet Cell (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Renal Cell (1)  ·  Carcinoma, Squamous Cell (1)  ·  Carcinoma, Transitional Cell (1)  ·  Chordoma (1)  ·  Colorectal Neoplasms (1)  ·  Desmoid Tumors (1)  ·  Drug Resistant Epilepsy (1)

Interventions

Bevacizumab (2)  ·  Calcium Dobesilate (1)  ·  Dexamethasone (1)  ·  Fulvestrant (1)  ·  Gemcitabine (1)  ·  Lomustine (1)  ·  Nivolumab (1)  ·  Radiation (1)  ·  Radiotherapy (1)  ·  Temozolomide (1)  ·  adagrasib (1)  ·  marizomib (1)  ·  pazopanib (1)  ·  pomalidomide (1)

Countries

United States (16)  ·  Puerto Rico (1)  ·  South Korea (1)

Top investigators

Willis Navarro, MD (2)  ·  Andrew J. Yee, MD (1)  ·  Christina Washington, MD (1)  ·  Erlinda M Gordon, MD (1)  ·  James McKiernan, MD (1)  ·  Jason Hauptman, MD, PhD (1)  ·  Lee Cranmer, MD (1)  ·  Leonor Nazareno (1)  ·  Marc Simon, MD (1)  ·  Robert Ramirez, DO (1)

Results publications

PMID 24089446, PMID 31401903, PMID 34637337, PMID 38427923, PMID 41424265

NIH funding

R42CA171552 (1)